The pharmaceutical company plans to open a new model of "new three-plate-H-shares and A-shares"

Pharmaceutical Network Corporate News : Recently, already in the new three-board market, H-share market has a map of Junshi Bio announced that it will be again punched in the science and technology boardIf the company successfully listed in the Science and Technology board, it means that the company will open a "new three-board and H-shares and A-shares" three-place listing model
Data show that Junshi Bio is an innovative-driven biopharmaceutical company with complete industry-wide capabilities from the discovery of innovative drugs, clinical research and development on a global scale, mass production to commercialization
On August 13, 2015, Junshi Bio was listed in the stock transfer system and publicly transferred, and after the listing was launched in December of that year, the first targeted issue of stock financing, involving a total amount of 350 million yuan; Stock financing, raising 250 million yuan, followed by June, August, January 2017 and February 2018, Junshi Bio has been financing a series of funds involving 30.6 million yuan, 368.1 million yuan, 319.7 million yuan, 299.7 million yuanAt the same time, Junshi Bio also issued 200 million yuan of convertible bonds in 2018
In December 2018, Junshi Bio reissued H shares and listed on the Hong Kong Stock Exchange, with plans to raise 2.7 billion yuan, of which 1.2 billion yuan was invested in innovative drug research and development projects and 800 million yuan was used to repay bank loans and replenish liquidity
On September 26, 2019, Junshi Bio-Filing Science Plate was accepted, and the company has completed only two rounds of inquiries, and the IPO process is quite efficient
Research and development and innovation capability is the company's core competitivenessIn terms of research and development investment, in 2016-2019, the company's research and development expenditure was RMB12.200.13 million, RMB275.334 million, RMB53.8828 million, RMB946.1 million, with a very high annual compound growth rateIn addition, according to Junshi Bio's plan, the next three years of research and development investment (including cooperative projects) funding needs of about 4.03 billion yuan
In terms of innovation, the company had 20 products under study as of March 9Among them, the core product Toripalimab mono-anti-injection (commodity name: Tuyi) was approved by the State Drug Administration on December 17, 2018, is the first domestic approved listed domestic PD-1 monoclonal antibody injection, used to treat local or progressive melatomoma after the failure of previous standard treatmentIn addition, nine products have been approved by IND and 11 are in the preclinical research phase, of which DAC-002 (injection recombinant humanized anti-Trop2 monoantigen-Tub196 coupling agent) has submitted an IND application to NMPA and accepted
Financial data show that from 2018 to 2019, Junshi Bio's operating income was RMB29,276 million and RMB775 million, net profit was RMB723 million and RMB776 million, respectively, and net cash flow from operating activities was RMB 517 million and RMB1,179 million, respectivelyThe Company expects to achieve operating income of RMB150 million to RMB200 million in January-March 2020 and net profit attributable to shareholders of the parent company of RMB 233 million to RMB198 million
Although the company is still not profitable after the listing, revenue has soared The company chose the fifth listing criteria: the estimated market value is not less than 4 billion yuan, the main business or products need to be approved by the relevant departments of the state, the market space is large, has achieved phased results Pharmaceutical industry enterprises need at least one core product approved for Phase II clinical trials, and other companies that meet the positioning of the science and technology board need to have obvious technical advantages and meet the corresponding conditions.